Gliomas are the most common lethal brain tumours and remain great heterogeneity in terms of histopathology and clinical outcomes. Among them, glioblastomas are the most aggressive tumours that lead to a median of less than one-year survival in patients. Despite the little improvement of in diagnosis and treatments for last decades, there is an urgent need for prognostic markers to distinguish high- and low-risk patients before treatment.Here, we generated a list of genes associated with glioblastoma progressions and then performed a comprehensive statistical modelling strategy to derive a 10-gene (GLO10) score from genome wide expression profiles of a large glioblastoma cohort (n=844). Our study demonstrated that the GLO10 score could successfully distinguish high- and low-risk patients with glioblastomas regardless their traditional pathological factors. Validated in four independent cohorts, the utility of GLO10 score could provide clinicians a robust prognostic prediction tool to assess risk levels upfront treatments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642606 | PMC |
http://dx.doi.org/10.18632/oncotarget.20195 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!